CJC-1295 No DAC, also known as Modified GRF (1-29), represents a foundational peptide in preclinical growth hormone secretagogue investigations. Developed to overcome the rapid enzymatic degradation of native growth hormone-releasing hormone (GHRH), this synthetic tetrasubstituted peptide enables researchers to study physiological pulsatile GH release kinetics in vitro and in vivo. PX1 Research supplies high-purity CJC-1295 No DAC validated by independent HPLC and mass spectrometry testing for specialized laboratory applications.
CJC-1295 No DAC, also known as Modified GRF (1-29), represents a foundational peptide in preclinical growth hormone secretagogue investigations. Developed to overcome the rapid enzymatic degradation of native growth hormone-releasing hormone (GHRH), this synthetic tetrasubstituted peptide enables researchers to study physiological pulsatile GH release kinetics in vitro and in vivo. PX1 Research supplies high-purity CJC-1295 No DAC validated by independent HPLC and mass spectrometry testing for specialized laboratory applications.
In modern GHRH analog research, CJC-1295 No DAC (Modified GRF 1-29) serves as a primary tool for evaluating receptor-ligand kinetics, somatotroph signaling, and downstream insulin-like growth factor 1 (IGF-1) transcription. Native GHRH (1-44) and its biological fragment GRF (1-29) exhibit an extremely short plasma half-life in animal models, typically under 12 minutes, due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) between the Tyr1 and Ala2 residues.
To extend chemical stability while preserving biological activity at the GHRH receptor (GHRH-R), researchers synthesized CJC-1295 No DAC by introducing targeted amino acid substitutions at positions 2, 8, 15, and 27. These chemical modifications render the molecule highly resistant to enzymatic cleavage, allowing preclinical researchers to model controlled, pulsatile growth hormone secretion without altering the natural physiological feedback architecture of the hypothalamic-pituitary axis.
Investigating the cjc-1295 no dac research peptide allows laboratory teams to isolate the specific effects of short-acting GHRH stimulation from long-acting continuous agonists. Access to fully characterized reference materials is available through our main research catalog, ensuring consistent baseline data across experimental replicates.
The molecular architecture of CJC-1295 No DAC consists of a 29-amino-acid chain with four key substitutions relative to native GRF (1-29). The sequence is Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. The inclusion of D-alanine at position 2 directly inhibits DPP-IV cleavage, which is the primary inactivation pathway for endogenous GHRH.
Further stabilization is achieved through substitutions at position 8 (glutamine to alanine), position 15 (glycine to alanine), and position 27 (methionine to leucine). Substituting methionine with leucine prevents oxidative degradation during storage and incubation, enhancing physical stability in aquatic reconstitution buffers. Together, these modifications increase the functional half-life in rodent models from minutes to approximately 30 minutes, ideal for capturing biological pulse dynamics.
Understanding these structural modifications is essential when designing comparative assays across the broader family of research peptides. The structural integrity of Mod GRF 1-29 ensures high affinity for GHRH-R on anterior pituitary somatotrophs, activating G-protein-coupled receptor pathways without off-target binding.
A critical distinction in secretagogue research involves comparing the short-acting CJC-1295 No DAC against the long-acting CJC 1295 DAC GHRH analog. The inclusion of the Drug Affinity Complex (DAC)—a reactive maleimide linker attached to the lysine residue at position 30—fundamentally changes the peptide's pharmacokinetics by covalently binding to circulating serum albumin post-administration.
In preclinical animal models, CJC-1295 with DAC demonstrates an extended half-life exceeding 6 to 8 days, leading to sustained, continuous elevations in baseline GH and IGF-1 levels. While beneficial for studying chronic baseline elevation, continuous activation can alter standard pituitary refractory dynamics. Conversely, CJC-1295 No DAC lacks the maleimide linker and does not bind albumin, making it the preferred compound for studying natural, pulsatile somatotroph firing patterns.
Researchers evaluating tissue repair, protein synthesis pathways, and acute receptor desensitization often prefer Mod GRF 1-29 due to its transient signaling duration. For comparative study designs, laboratories frequently cross-reference data obtained from CJC-1295 with DAC against non-DAC variants to map baseline versus episodic receptor stimulation.
Upon binding to the GHRH receptor on anterior pituitary cells, CJC-1295 No DAC stimulates the Gs alpha subunit, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. This cascade activates protein kinase A (PKA), leading to the influx of extracellular calcium via L-type voltage-gated calcium channels and triggering the exocytosis of stored growth hormone granules.
Preclinical rodent studies indicate that transient GH release driven by CJC-1295 No DAC leads to downstream hepatic transcription of IGF-1 via the JAK2/STAT5B signaling pathway. Elevated local and systemic IGF-1 levels facilitate nitrogen retention, satellite cell activation in skeletal muscle tissue, and extracellular matrix remodeling in chondrocyte and fibroblast cell culture models.
Because CJC-1295 No DAC maintains a physiological pulse profile, it avoids the continuous receptor internalization often observed with prolonged continuous exposure. Consequently, it remains a gold-standard reference compound in broader growth hormone secretagogue studies investigating metabolic modulation, lipid oxidation, and cellular repair mechanisms.
In dual-agonist research protocols, scientists frequently co-administer GHRH analogs with Growth Hormone Secretagogue Receptor (GHSR-1a) agonists to study intracellular signal cross-talk. While GHRH analogs operate via the cAMP/PKA pathway, ghrelin mimetics stimulate the phospholipase C (PLC) / inositol trisphosphate (IP3) pathway, releasing intracellular calcium from the endoplasmic reticulum.
When a GHRH analog like CJC-1295 No DAC is combined with selective ghrelin mimetics such as Ipamorelin, GHRP-2, or GHRP-6, in vitro and animal models demonstrate a synergistic release of GH that significantly exceeds the additive total of either compound administered alone. This dual-pathway activation amplifies total peak amplitude without raising prolactin or cortisol to non-physiological levels.
Additionally, baseline comparisons with older GHRH fragments like Sermorelin illustrate the superior chemical stability of CJC-1295 No DAC, as Sermorelin lacks the stabilizing D-Ala2 substitution and succumbs more rapidly to DPP-IV hydrolysis in plasma incubations.
To achieve reproducible results in preclinical testing, researchers must source peptides that meet strict chemical identity and purity standards. Substandard research compounds containing synthesis byproducts, truncated sequences, or residual TFA (trifluoroacetic acid) can confound cellular assays and yield unpredictable signaling data.
PX1 Research enforces rigorous quality control protocols across all peptide lots, ensuring every batch meets the highest analytical standards before release:
• Purity Verification: Every lot achieves ≥98% purity verified via high-performance liquid chromatography (RP-HPLC). • Mass Identity: Molecular weight and primary sequence confirmation performed via Electrospray Ionization Mass Spectrometry (ESI-MS). • Endotoxin Testing: Quantified via Limulus Amebocyte Lysate (LAL) assay to guarantee levels <0.01 EU/μg, preventing inflammatory artifacts in cell culture. • Analytical Documentation: Certificate of Analysis (COA) containing raw chromatograms provided for every single lot. • Domestic Synthesis: All synthesis and purification processes take place in ISO 17025 accredited, US-based laboratories.
Researchers seeking to buy CJC-1295 No-DAC Mod GRF 1-29 can review complete batch documentation directly on our platform prior to procurement.
CJC-1295 No DAC is supplied as a sterile, lyophilized cake to ensure long-term peptide stability. For optimal shelf life, un-reconstituted vials should be stored at -20°C to -80°C in a dry environment away from light exposure. Under these conditions, the lyophilized peptide remains stable for up to 24 months.
For laboratory reconstitution, researchers should utilize sterile bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the specific cell culture or animal model. The diluent should be introduced gently along the glass wall of the vial to minimize shear stress on the peptide structure. Gentle swirling is recommended; aggressive agitation or vortexing should be avoided as it may cause peptide aggregation.
Following reconstitution, liquid solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles, which degrade the primary structure. Reconstituted CJC-1295 No DAC solutions remain stable at 2°C to 8°C for up to 30 days. For large-scale studies requiring high volume, specialized procurement options are managed via our wholesale lab account portal.
PX1 Research serves as a trusted partner for academic institutions, biotechnology enterprises, and independent research facilities across the United States. We recognize that high-throughput screening and longitudinal animal studies require absolute batch-to-batch consistency and total supply chain transparency.
All orders ship directly from our domestic fulfillment hubs in California and Arizona. Orders placed before 12:00 PM PST Monday through Friday qualify for same-day dispatch, minimizing transit time and mitigating thermal stress on temperature-sensitive research reagents.
By enforcing strict USA manufacturing standards, providing complete HPLC/MS analytical data, and maintaining inventory redundancy across multiple distribution centers, PX1 Research delivers the reliability necessary for advanced GHRH analog research.
What is CJC-1295 No DAC used for in ghrh analog research?
In ghrh analog research, CJC-1295 No DAC (Mod GRF 1-29) is used as a short-acting GHRH receptor agonist to investigate pulsatile growth hormone secretion, somatotroph signaling cascades, downstream IGF-1 gene expression, and tissue repair mechanisms in animal and cell culture models.
Where can laboratories buy cjc-1295 no-dac mod grf 1-29?
Laboratories can buy cjc-1295 no-dac mod grf 1-29 directly from PX1 Research. We provide USA-manufactured research peptides accompanied by lot-specific Certificates of Analysis (COA), HPLC purity testing, and mass spectrometry validation for qualified research entities.
What is the difference between cjc 1295 dac ghrh analog and CJC-1295 No DAC?
The cjc 1295 dac ghrh analog contains a Drug Affinity Complex (DAC) that binds to serum albumin, extending its biological half-life to over a week for continuous GH elevation. CJC-1295 No DAC lacks this complex, yielding a shorter half-life (~30 minutes) that mimics natural physiological GH pulses.
Why is the cjc-1295 no dac research peptide preferred for pulsatile GH studies?
The cjc-1295 no dac research peptide is preferred because its transient pharmacokinetic profile activates GHRH receptors without causing long-term receptor desensitization or altering baseline refractory cycles, allowing precise measurement of episodic GH release.
What purity levels are guaranteed for CJC-1295 No DAC from PX1 Research?
PX1 Research guarantees a minimum purity of ≥98% for CJC-1295 No DAC, verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS).
What are the endotoxin thresholds for PX1 Research peptides?
All peptide lots undergo rigorous endotoxin testing via the Limulus Amebocyte Lysate (LAL) assay to ensure levels remain below 0.01 EU/μg, preventing unwanted inflammatory responses during sensitive cellular assays.
How should CJC-1295 No DAC be reconstituted for lab applications?
CJC-1295 No DAC should be reconstituted using sterile bacteriostatic water or sterile saline. The diluent should be trickled down the inner glass wall of the vial and gently swirled until fully dissolved, avoiding aggressive shaking.
How should reconstituted CJC-1295 No DAC be stored?
Once reconstituted, liquid solutions should be stored at 2°C to 8°C for up to 30 days. For long-term storage, solutions should be divided into single-use aliquots and maintained at -20°C or -80°C to prevent degradation from freeze-thaw cycles.
How does CJC-1295 No DAC differ structurally from native Sermorelin?
While both share the core 29-amino-acid GRF sequence, CJC-1295 No DAC features four chemical substitutions (D-Ala2, Ala8, Ala15, Leu27) that confer resistance to DPP-IV enzymatic cleavage, granting it greater metabolic stability than native Sermorelin.
Where does PX1 Research ship CJC-1295 No DAC from?
PX1 Research ships all research compounds from domestic fulfillment facilities located in California and Arizona, offering same-day shipping for orders placed Monday through Friday before 12:00 PM PST.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.